Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Carcinoma of Unknown Primary Clinical Trial

Official title:

An Open-label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00873119
• Other study ID #: PXD101-CLN-17
• Status: Completed
• Phase: Phase 2
• First received: March 31, 2009
• Last updated: July 7, 2015
• Start date: February 2009
• Est. completion date: December 2012

Study information

• Verified date: July 2015
• Source: Onxeo
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.

Description:

This is an open-label, multinational, multicenter, randomized, comparative efficacy and safety study in previously untreated patients with carcinoma of unknown primary. Patients meeting inclusion and exclusion criteria will be randomized to treatment in Arm A (BelCaP) or Arm B (CaP).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 89
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with CUP where the primary site had not been revealed by complete history, physical examination (including gynecological examination when appropriate), computed tomography (CT) scan of the chest, abdomen and pelvis, bilateral mammography (in women with adenocarcinoma or poorly differentiated carcinoma), routine laboratory studies (complete blood cell counts, electrolytes, urinalysis, liver and renal function tests), and directed work-up of any other symptomatic areas.

• Light microscopic pathologic diagnosis of adenocarcinoma (including poorly differentiated), squamous cell carcinoma, or poorly differentiated carcinoma. Patients with poorly differentiated carcinoma must have immunohistochemical stains to confirm the diagnosis of carcinoma, and to rule out other tumor types. Note: patients with a light microscopic histology diagnosis of "poorly differentiated neoplasm, not otherwise classified" did not fulfill the criteria for inclusion, unless immunohistochemical staining confirmed the diagnosis of carcinoma.

• Signed consent of an IRB ([Institutional Review Board])/IEC ([Independent ethics committee]) approved ICF ([Informed Consent Form]).

• At least one measurable lesion according to RECIST ([response evaluation criteria in solid tumors ]) criteria. Note, target lesions could only be selected within previously irradiated areas if newly arising or clearly progressing after irradiation as proven by repeat scanning

• Performance status Eastern Cooperative Oncology Group (ECOG) = 2.

• Age = 18 years.

• A negative serum or urine pregnancy test for women of childbearing potential. Postmenopausal women must have been amenorrheic for = 12 months to be considered of non-childbearing potential.

• Serum potassium within normal range.

• Acceptable coagulation status: Prothrombin time/International normalized ratio PT/INR ([international normalized ratio]), and activated partial thromboplastin time (APTT) = 1.5 × upper limit of normal (ULN) or in the therapeutic range if on anticoagulation therapy.

• Acceptable liver, renal and bone marrow function including the following:

1. Bilirubin = 1.5 times ULN (if liver metastases were present, then = 3 × ULN was allowed).

2. Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine amino transferase/serum glutamic pyruvic transaminase (ALT/SGPT), and alkaline phosphatase = 3 times ULN (if liver metastases were present, then = 5 × ULN was allowed).

3. An estimated creatinine clearance = 45 mL/min using an appropriate formula (Appendix C, protocol version 1.0, Appendix 16.1.1), or measured ethylenediaminetetraacetic acid (EDTA) renal clearance = 45 mL/min.

4. Absolute neutrophils count = 1.5 × 109/L, platelets = 100 × 109/L.

5. Hemoglobin = 9.0 g/dL or = 5.6 mmol/L (patients with chronic anemia due to underlying disease and its treatment could undergo blood transfusion prior to treatment in order to meet this criteria).

Exclusion Criteria:

• Patients with well recognized subsets of CUP site where treatments directed towards a defined tumor type, or surgery, alternatively radiotherapy, can be advised:

• Women with adenocarcinoma involving only axillary lymph nodes.

• Women with papillary serous carcinoma of the peritoneum.

• Women with adenocarcinoma with positive staining for estrogen receptor (ER) or progesterone receptor.

• Young men (< 45 years) with poorly differentiated carcinoma consistent with an extragonadal germ cell tumor (carcinoma involving mediastinum or retroperitoneum, or elevated levels of beta-human chorionic gonadotropin or alpha-fetoprotein).

• Men with bone metastases and/or adenocarcinoma, and abnormally elevated PSA ([Prostate specific antigen]) in their plasma.

• Patients with squamous cell carcinoma involving only cervical lymph nodes, or inguinal lymph nodes.

• Patients with neuroendocrine carcinomas determined according to standard pathology diagnosis procedures, including stains.

• Patients with potentially completely resectable metastatic disease, or disease which can be adequately treated with radiotherapy only.

• Patients with brain or meningeal metastases. Note, patients with adequately treated brain metastases, e.g. surgically resected, or adequately controlled by radiotherapy, with no residual neurological symptoms due to metastases and no steroid treatment required, could be enrolled. If clinical suspicion, adequate investigations should be performed to rule out brain metastases or meningeal involvement.

• Prior systemic anti-tumor therapy, including chemotherapy administered in association to radiotherapy for sensitization, for CUP. Note, prior radiotherapy or surgery was allowed provided treatment was completed at least 4 weeks before randomization.

• Treatment with investigational agents, including non-anti-tumor agents, within the last 4 weeks before randomization.

• Co-existing active severe infection or any co-existing medical condition assessed by the Investigator as likely to interfere with study procedures.

• Significant cardiovascular disease (New York Heart Association Class III or IV cardiac disease), myocardial infarction within the past 6 months, unstable angina, unstable arrhythmia or a need for anti-arrhythmic therapy (use of medication to control heart rate in patients with atrial fibrillation was allowed, if on stable medication for at least the last month prior to randomization and the medication not listed as causing Torsade de Points (Section 13.2, Appendix B, protocol version 1.0, Appendix 16.1.1), or evidence of acute ischemia on ECG.

• Marked baseline prolongation of QT/QTc ([corrected QT interval]) interval, i.e., demonstration of a QTc interval > 450 millisecond (ms); Long QT Syndrome; the required use of concomitant medication that may cause Torsade de Pointes (Section 13.2, Appendix B, protocol version 1.0, Appendix 16.1.1).

• Altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures.

• History of a previous malignancy within 5 years with the exception of non-metastatic non-melanoma skin cancer or cervical carcinoma in situ. Prior systemic therapy for other malignancy completed at least 5 years before randomization is allowed.

Implemented with amendment 2 (study centers in France only): History of a previous malignancy, irrespective of time since diagnosis/treatment, with the exception of non metastatic non-melanoma skin cancer or cervical carcinoma in situ.

• Known hypersensitivity to either platinum compounds or paclitaxel, or any components of the study medications, and inability for desensitization.

• Known infection with HIV, or known active Hepatitis B or C infection.

• Peripheral neuropathy = Grade 2.

• Pregnant or lactating females.

• Women of childbearing age and potential who are not willing to use effective contraception during the study and until 30 days after last dose of study drug. Male patients or male patients who have female partners of childbearing age and potential who are not willing to use effective contraception during the study and until 30 days after last dose of study drug. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices, sexual abstinence or vasectomized partner.

• Patients that are not affiliated with social security (study centers in France only).

• Implemented with amendment 1 (study centers in Denmark only): Hearing impairment assessed by the Investigator as being of such a degree that treatment with carboplatin cannot be initiated.

• Implemented with amendment 1 (study centers in Denmark only): Bleeding tumors.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma of Unknown Primary
• Neoplasms, Unknown Primary

Intervention

Drug:
• belinostat, carboplatin, paclitaxel

• carboplatin, paclitaxel

Locations

Country	Name	City	State
Denmark	H:S Rigshospital, The Finsen Centre	Copenhagen
France	CRLCC Francois Baclesse, Oncologie medicale	Caen
France	Centre Oscar Lambert	Lille
France	Centre Léon Bérard, Oncologie	Lyon
France	Centre Eugène Marquis	Rennes cedex
France	Centre Henri Becquerel, Oncologie Médicale	Rouen
France	Institut de Cancerologie de la Loire	Saint Priest en Jarez
France	Institut Gustave Roussy IGR	Villejuif cedex
Germany	Carl-Gustav-Carus Medicinische Klinik und Poliklinik I	Dresden
Germany	Kliniken Essen-Mitte	Essen
Germany	ASKLEPIOS Klinik Altona	Hamburg
Germany	Ostholstein-Onkologie	Oldenburg in Holstein
United States	Baton Rouge Medical Center	Baton Rouge	Louisiana
United States	Center for Cancers and Blood Disorders	Bethesda	Maryland
United States	Chattanooga Oncology & Hematology Associates, PC	Chattanooga	Tennessee
United States	Oncology Hematology Care Inc.	Cincinnati	Ohio
United States	South Carolina Oncology Associates	Columbia	South Carolina
United States	Florida Cancer Specialists	Fort Myers	Florida
United States	Research Medical Center	Kansas City	Missouri
United States	Northwest Georgia Oncology Centers	Marietta	Georgia
United States	Tennessee Oncology Sarah Cannon Research	Nashville	Tennessee
United States	Virginia Cancer Institute	Richmond	Virginia
United States	South Texas Oncology and Hematology	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Onxeo	Spectrum Pharmaceuticals, Inc

Countries where clinical trial is conducted

United States,  Denmark,  France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	Time from the date of randomization to the time of disease progression or death due to any cause, measured by RECIST criteria (Response Evaluation Criteria In Solid Tumors).	Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study	No
Secondary	Best Overall Response	The best overall response in an individual patient according to the RECIST criteria (Eisenhauer 2009 ) is the best response recorded from the start of the treatment until disease progression/recurrence. Objective response is defined as best overall response of complete response (CR) or partial response (PR)	Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study	No
Secondary	Overall Survival (OS)	Time from the date of randomization to the date of death	Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study	No
Secondary	Time to Response	For patients with overall best response being CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status is recorded first) were met	Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study	No
Secondary	Duration of Response	Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date that PD ([Progressive Disease]) or death was documented	Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study	No
Secondary	Time to Progression (TTP)	Time from the date of randomization to the time of disease progression	Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study	No